1. A serine protease inhibitor, nafamostat mesilate, suppresses aldosterone secretions in vivo
- Author
-
Katsusuke Yano, Shin-ichiro Ozeki, Tatsuyuki Yamaguchi, Hirokuni Tetsuo, Masazumi Akahoshi, Shoichi Nagao, Hidefumi Yamazaki, and Shinji Seto
- Subjects
Male ,Proteases ,medicine.medical_specialty ,Serine Proteinase Inhibitors ,Physiology ,Blood Pressure ,Adrenocorticotropic hormone ,Plasma renin activity ,Inferior vena cava ,Guanidines ,chemistry.chemical_compound ,In vivo ,Internal medicine ,Renin–angiotensin system ,Adrenal Glands ,Renin ,Internal Medicine ,medicine ,Animals ,Rats, Wistar ,Infusions, Intravenous ,Aldosterone ,Serine protease ,biology ,Benzamidines ,Rats ,Endocrinology ,chemistry ,medicine.vein ,Regional Blood Flow ,biology.protein ,Cardiology and Cardiovascular Medicine - Abstract
To examine the role of serine proteases in the control of aldosterone (Ald) secretion, we studied the effects of nafamostat mesilate (Naf), a serine protease inhibitor, on in vivo Ald secretion and Ald content in the rat adrenal gland. Either Naf (2 mg/kg/h; n =10) or saline (2 ml/h; n =10) was administered intravenously for 30 min to anesthetized Wistar rats whose left adrenal vein was cannulated selectively via the inferior vena cava. Naf caused a significant decrease in Ald secretion rate compared to saline (1.99±0.32 vs. 3.42±0.56 ng/min, p
- Published
- 2005